Similar articles

• Orphan drugs and orphan tests in the USA.

  Thoene JG. Thoene JG. Community Genet. 2004;7(4):169-72. doi: 10.1159/000082255. Community Genet. 2004. PMID: 15692190 No abstract available.
• The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.

  Burke KA, Freeman SN, Imoisili MA, Coté TR. Burke KA, et al. Clin Pharmacol Ther. 2010 Oct;88(4):449-53. doi: 10.1038/clpt.2010.193. Clin Pharmacol Ther. 2010. PMID: 20856241 Review.
• The Minor Use and Minor Species Animal Health Act: past, present, and future.

  Haley CJ. Haley CJ. Food Drug Law J. 2006;61(1):13-43. Food Drug Law J. 2006. PMID: 16838456 No abstract available.
• Adopting orphan drugs--two dozen years of treating rare diseases.

  Haffner ME. Haffner ME. N Engl J Med. 2006 Feb 2;354(5):445-7. doi: 10.1056/NEJMp058317. N Engl J Med. 2006. PMID: 16452556 No abstract available.
• Translation of rare disease research into orphan drug development: disease matters.

  Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL. Heemstra HE, et al. Drug Discov Today. 2009 Dec;14(23-24):1166-73. doi: 10.1016/j.drudis.2009.09.008. Epub 2009 Oct 7. Drug Discov Today. 2009. PMID: 19818412 Review.